Wei Cheng Lu
About Wei Cheng Lu
Wei Cheng Lu is a Principal Scientist at Alloy Therapeutics, Inc., specializing in protein-based therapeutics and enzyme engineering. He holds two issued US patents and has extensive experience in mammalian cell-surface display and high-throughput screening.
Work at Alloy Therapeutics
Wei Cheng Lu has been serving as a Principal Scientist at Alloy Therapeutics, Inc. since 2021. In this role, he focuses on the development of protein-based therapeutics, leveraging his expertise in enzyme engineering and directed evolution. His contributions include engineering enzymes to utilize new substrates for therapeutic applications, particularly in the treatment of cancer and genetic diseases.
Education and Expertise
Wei Cheng Lu earned his Doctor of Philosophy (Ph.D.) in Biochemistry from The University of Texas at Austin, where he studied from 2006 to 2013. His academic focus included directed evolution and enzyme engineering for therapeutics. This strong educational foundation supports his current research and development efforts in protein-based therapeutics.
Background
Before joining Alloy Therapeutics, Wei Cheng Lu held various positions in the biotechnology field. He worked as a Scientific Consultant at Aeglea BioTherapeutics from 2015 to 2019 and served as a Postdoctoral Fellow at The University of Texas at Austin from 2014 to 2019. Additionally, he was a Senior Scientist at Arbor Biotechnologies from 2019 to 2021, where he designed and optimized a high-throughput screening and selection platform.
Patents and Innovations
Wei Cheng Lu holds two issued US patents and has one filed US patent in the field of protein-based therapeutics. His work involves engineering enzymes to utilize new substrates, which contributes to advancements in therapeutic solutions for cancer and genetic diseases.
Technical Skills and Experience
Wei Cheng Lu possesses hands-on experience in mammalian cell-surface display techniques, employing transient transfection and retroviral transduction methods. His technical skills are complemented by his expertise in high-throughput screening and selection processes, which he developed during his time at Arbor Biotechnologies.